Principal Investigator
James Hoffman
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240173
Clinical Trial Summary
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL Amyloidosis
Phase
Phase III
Funding Agency/Sponsor
National Cooperative Group
Disease
Myeloma
Contact Information
Phone Number
305-243-2647